CDKN1A and in situ carcinoma: We employed the pan-caspase inhibitor zVAD-fmk, which prevented the accumulation of γH2AX and decreased caspase 3 cleavage, proving its effectiveness, but did not reverse the decrease in p21 CIP1 after CIS (Fig. 4E).